Eyepoint, Inc. · NASDAQ:EYPT

Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (February 2025)

31 slides from Eyepoint's investor presentation, Feb 5, 2025

  1. Slide 1: Investor Presentation February 2025

    Investor Presentation February 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2

  2. Slide 2: Legal Disclaimers

    Legal Disclaimers ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate

  3. Slide 3: EyePoint: The Leader in Sustained Release Drug Delivery for Retinal Disease

    EyePoint: The Leader in Sustained Release Drug Delivery for Retinal Disease ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Most robust dataset in wet AMD and DME among all sustained delivery programs in development Two ongoing global Phase 3 non-inferiority pivotal trials in wet AMD Stron

  4. Slide 4: Pipeline Leveraging Durasert E Drug Delivery Technology

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. wet AMD, wet age-related macular degeneration; DME, diabetic macular edema; PK, pharmacokinetic; GA, geographic atrophy Pipeline Leveraging Durasert E™ Drug Delivery Technology trial underway non-clinical Durasert E™ Programs Indication Disco

  5. Slide 5: Durasert E Technology: Sustained-Release Drug Delivery

    IVT, intravitreal DURASERT E™ TECHNOLOGY Sustained-Release Drug Delivery Standard in-office IVT injection Continuous dosing Zero-order kinetics drug release Bioerodible Durasert E™: Solid injectable insert Drug formulated within a bioerodible matrix Designed to release drug load before matrix fully

  6. Slide 6: Vorolanib is a Best-In-Class TKI that Selectively Inhibits all Forms of the VEGF Receptor

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. Bakri SJ, et al. PLoS One. 2024;19(6):e0304782 [CC BY 4.0]. TKI tyrosine kinase inhibitor; AMD, age-related macular degeneration; Ang, angiopoietin; FGF(R), fibroblast growth factor (receptor); PDGF(R), platelet-derived growth factor (rece

  7. Slide 7: DURAVYU: Vorolanib in Bioerodible Durasert E

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Immediately bioavailable – reaches therapeutic levels within hours Constant dosing – zero-order kinetics release for at least six months Controlled drug release – bioerodible matrix controls drug release; no free-floating drug Contains NO PEG

  8. Slide 8: DURAVYU Demonstrated Positive Efficacy and Favorable Safety Profile Across Multiple Clinical Trials

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU Demonstrated Positive Efficacy and Favorable Safety Profile Across Multiple Clinical Trials and Indications 1. Data as of January 16, 2025. Preliminary data pending final analysis. Wet AMD, wet age-related macular degeneration; NPDR,

  9. Slide 9: Phase 2 VERONA Clinical Trial in DME – Six-Month Results

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 VERONA Clinical Trial in DME – Six-Month Results Immediate Bioavailability and sustained delivery for At Least Six months DME, diabetic macular edema Data as of January 16, 2025. Preliminary data pending final analysis.

  10. Slide 10: Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need

    Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need for More Durable Treatments ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. William R. Rowley, Clement Bezold, Yasemin Arikan, et al. Diabetes 2030: Insights from Yesterday, Today and Future Trends. PubMed Cent

  11. Slide 11: Phase 2 VERONA Clinical Trial is a Randomized, Open-Label, Aflibercept Controlled Trial

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DME, diabetic macular edema; VEGF, vascular endothelial growth factor; BCVA, best corrected visual acuity; OCT, optical coherence tomography; CST, central subfield thickness DURAVYU dosing Visit Scheduled aflibercept injection Sham injection

  12. Slide 12: VERONA Clinical Trial Supplement Criteria

    VERONA Clinical Trial Supplement Criteria ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. vs. best on study measurement; 2. as measured by Spectral domain OCT (SD-OCT) BCVA, best corrected visual acuity; PRN, pro re nata; CST, central subfield thickness Starting at Week 4: Reduction in

  13. Slide 13: VERONA: Phase 2 Clinical Trial Met Primary and Secondary Endpoints

    VERONA: Phase 2 Clinical Trial Met Primary and Secondary Endpoints Data supports DURAVYU as a Potential Treatment for DME with improvement in vision and anatomy with superior dosing intervals ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2.7mg - 24 WEEK EFFICACY Results: Primary

  14. Slide 14: VERONA: Single DURAVYU 2.7mg Treatment Demonstrated Clinically Meaningful Improvement in BCVA

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. VERONA: Single DURAVYU 2.7mg Treatment Demonstrated Clinically Meaningful Improvement in BCVA; Supports Noninferiority in Pivotal Trial BCVA, best-corrected visual acuity; VA, visual acuity Data as of January 16, 2025. Preliminary data pendin

  15. Slide 15: VERONA: DURAVYU 2.7mg Demonstrated Improved and Controlled Anatomy

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. VERONA: DURAVYU 2.7mg Demonstrated Improved and Controlled Anatomy with 74% More Drying than Aflibercept Control CST: central subfield thickness Data as of January 16, 2025. Preliminary data pending final analysis. Source: Independent reading

  16. Slide 16: VERONA: Greater Proportion of Supplement-Free Eyes vs. Aflibercept Control

    VERONA: Eyes Treated with DURAVYU had a Greater Proportion of Supplement-Free Eyes vs. Aflibercept Control up to Six Months ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Data as of January 16, 2025. Preliminary data pending final analysis. 2.7mg DURAVYU reduced treatment burden by over t

  17. Slide 17: Phase 2 VERONA Clinical Trial Case Study - 2.7mg Dose

    Phase 2 VERONA Clinical Trial Case Study 1 - 2.7mg Dose Pt - Immediate Drying with Improved Vision After Single DURAVYU Treatment and No Supplementation - Prior treatment = 2x Eylea, 1x Vabysmo in past 12 months ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Day 1 BCVA: 46 Week 4 BCVA: 65

  18. Slide 18: Phase 2 VERONA Clinical Trial Case Study - 2.7mg Dose Patient

    Phase 2 VERONA Clinical Trial Case Study 2 - 2.7mg Dose Patient- Continued Drying at Week 24 with Improved VA After Single DURAVYU Treatment and No Supplementation - Prior treatment = 1x Avastin, 5x Vabysmo in past 7 months ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Day 1 BCVA: 73 Wee

  19. Slide 19: Continued Favorable Safety and Tolerability Profile in VERONA Clinical Trial

    Continued Favorable Safety and Tolerability Profile in VERONA Clinical Trial ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. SAE, serious adverse event Data as of January 16, 2025. Preliminary data pending final analysis. No reported DURAVYU-related ocular SAEs or systemic SAEs No cases of

  20. Slide 20: VERONA: Phase 2 Clinical Trial Highlights

    VERONA: Phase 2 Clinical Trial Highlights ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Data as of January 16, 2025. Preliminary data pending final analysis. Primary endpoint met for both DURAVYU doses Demonstrated immediate clinical bioavailability Achieved clinically meaningful results

  21. Slide 21: Positive Phase 2 VERONA Data Supports Advancement to Phase 3 Pivotal Program

    Positive Phase 2 VERONA Data Supports Advancement to Phase 3 Pivotal Program – Expected Initiation by End of 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Next Steps: Continue development of Phase 3 clinical protocol – non-inferiority design Discuss Phase 2 results and proposed Phas

  22. Slide 22: DURAVYU LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD NON-INFERIORITY VERSUS AN AFLIBERCEPT CONTROL

  23. Slide 23: Phase 3 Trials are Designed to Enable Global Regulatory Approvals for DURAVYU

    Phase 3 Trials are Designed to Enable Global Regulatory Approvals for DURAVYU ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Demonstrate DURAVYU, when administered every six months, achieves similar visual outcomes to on-label aflibercept while reducing treatment burden ~400 patients per

  24. Slide 24: DURAVYU in Wet AMD Phase 3 Pivotal Trial Design

    DURAVYU™ in Wet AMD Phase 3 Pivotal Trial Design ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Screening D1 W4 W8 W12 W16 W24 W32 W84-W92 W20 W28 DURAVYU™ 2.7mg Aflibercept 2mg q8W RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION VISIT VISIT SCHEDULED DURAVYU™ DOSE AFLIBERCEPT q8W 1⁰ ENDPOIN

  25. Slide 25: Exceptional Enrollment to Date Driven by Significant Investigator and Patient Enthusiasm

    Exceptional Enrollment to Date Driven by Significant Investigator and Patient Enthusiasm ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. June 2024 Final Phase 3 protocols October 2024 First patient in LUGANO trial dosed December 2024 First patient in LUCIA trial dosed 2H 2025 Expected full

  26. Slide 26: Commercial Manufacturing Facility Opened in October 2024

    Commercial Manufacturing Facility Opened in October 2024 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. FDA, Federal Drug Administration; EMA, European Medicines Agency; cGMP, current good manufacturing practice Located in Northbridge, MA Built to US FDA and EU EMA standards 40,000sf cGMP

  27. Slide 27: EYP-2301: razuprotafib in Durasert E

    ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. EYP-2301: razuprotafib in Durasert E™ A sustained delivery tie-2 agonist for severe retinal diseases

  28. Slide 28: EYP-2301: Razuprotafib in Durasert E is a Patented TIE-2 Agonist

    EYP-2301: Razuprotafib in Durasert E™ is a Patented TIE-2 Agonist as a Potential New MOA for Treating Serious Retinal Diseases ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. Heier et al. Retina, 2021;41:1-19. and Joussen et al. Eye 2021; 35:1305-1316.; 2. Hammes, et. Al – Diabetes.2011

  29. Slide 29: On Track for Continued Execution And Well-Funded Through Key Anticipated DURAVYU Milestones

    On Track for Continued Execution And Well-Funded Through Key Anticipated DURAVYU Milestones ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DME, diabetic macular edema; EOP2, End of Phase 2; wet AMD, wet age-related macular degeneration; SAB, Scientific Advisory Board DURAVYU™ Corporate ✓

  30. Slide 30: EyePoint: The Leader in Sustained Release Drug Delivery for Retinal Disease

    EyePoint: The Leader in Sustained Release Drug Delivery for Retinal Disease ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Most robust dataset in wet AMD and DME among all sustained delivery programs in development Two ongoing global Phase 3 non-inferiority pivotal trials in wet AMD Stron

  31. Slide 31: Investor Presentation February 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

    Investor Presentation February 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint Pharmaceuticals — Investor Presentation (February 2025) on 6ix